BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jul 13, 2009
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 7/10 cls
Amgen Inc. (NASDAQ:AMGN) Baird Christopher Raymond Price target Market outperform 12% $57.81
Jefferies Eun Yang Price target Buy
UBS Maged Shenouda Price target Neutral
Raymond raised his target to $65 from $60 after Amgen reported that denosumab was superior to Zometa zoledronic acid on the primary endpoint of time to the first on-study skeletal related event in a Phase III trial to prevent SREs associated with breast cancer. The human mAb targeting receptor activator of NF-kappa B ligand (RANKL) was also superior to Zometa on the secondary endpoint of time to the first and subsequent on-study SREs. Novartis AG (NYSE:NVS; SIX:NOVN) markets Zometa (see "Denosumab Dreams," A15).

Read the full 775 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >